Compare Adaptive Biotechnologies Corp (ADPT) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Roundhill NVDA WeeklyPay ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Roundhill NVDA WeeklyPay ETF trades at $36.14. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | NVDW | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $22.37 | $53.42 |
52-Week Low | $10.24 | $31.88 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
NVDW trades at $34.32, down 0.38% on the day, with a bearish technical outlook indicated by moving averages and key indicators. The stock shows active dividend distributions, with multiple payouts in H1-26, but lacks available fundamental data such as P/E, revenue, or earnings metrics. No recent news or financial updates are accessible for deeper analysis.
The outlook is cautious due to the bearish technical signals and absence of current fundamental data. Investment opportunities hinge on future financial disclosures, while risks include potential underlying weaknesses and market volatility. Investors should await earnings reports for clarity on valuation and growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
